Connection

Co-Authors

This is a "connection" page, showing publications co-authored by BRYAN K KEE and VAN KARLYLE MORRIS.
Connection Strength

1.869
  1. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun. 2023 12 11; 3(12):2510-2517.
    View in: PubMed
    Score: 0.233
  2. Bintrafusp alfa, an anti-PD-L1:TGF-? trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun. 2022 09; 2(9):979-986.
    View in: PubMed
    Score: 0.214
  3. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol. 2022 Apr; 13(2):647-656.
    View in: PubMed
    Score: 0.207
  4. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6.
    View in: PubMed
    Score: 0.182
  5. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949.
    View in: PubMed
    Score: 0.151
  6. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
    View in: PubMed
    Score: 0.121
  7. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncol. 2024 Nov 01; 10(11):1519-1529.
    View in: PubMed
    Score: 0.062
  8. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunol Res. 2023 07 05; 11(7):925-945.
    View in: PubMed
    Score: 0.056
  9. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118.
    View in: PubMed
    Score: 0.056
  10. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 2023 Feb 13; 7(1):16.
    View in: PubMed
    Score: 0.055
  11. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open. 2022 10 03; 5(10):e2236357.
    View in: PubMed
    Score: 0.054
  12. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).
    View in: PubMed
    Score: 0.053
  13. Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.048
  14. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res. 2021 06 01; 27(11):3039-3049.
    View in: PubMed
    Score: 0.048
  15. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer. 2021 06; 20(2):137-147.e1.
    View in: PubMed
    Score: 0.047
  16. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer. 2020 12; 19(4):e189-e199.
    View in: PubMed
    Score: 0.046
  17. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2020 03; 19(1):48-56.e2.
    View in: PubMed
    Score: 0.044
  18. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.
    View in: PubMed
    Score: 0.043
  19. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019 02 01; 30(2):243-249.
    View in: PubMed
    Score: 0.042
  20. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279.
    View in: PubMed
    Score: 0.037
  21. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol. 2017 03 01; 28(3):642-650.
    View in: PubMed
    Score: 0.036
  22. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.